Drug Sponsors

MiReven, Silence to evaluate delivery of novel microRNA-based therapeutics

Wednesday, August 22, 2012 02:05 PM

Silence Therapeutics, an RNA interference (RNAi) therapeutics company, has signed an agreement with MiReven, an Australian-based microRNA company, to assess the delivery potential of Silence's proprietary delivery systems with MiReven's novel microRNA-based therapeutics.

More... »

Marina Biotech reduces board size, seeks funding

Wednesday, August 22, 2012 01:35 PM

Marina Biotech, a nucleic acid-based drug discovery and development company, continues to seek adequate funding to implement its business plan.

More... »

AIDS Healthcare Foundation acquires MOMS Pharmacy

Wednesday, August 22, 2012 10:44 AM

AIDS Healthcare Foundation (AHF), a global nonprofit HIV/AIDS organization has acquired MOMS Pharmacy, a specialty pharmacy focused exclusively on providing medications and support services to people living with HIV/AIDS.

More... »

South and Central America API market closing gap on northern neighbors

Wednesday, August 22, 2012 09:57 AM

More... »

Ipsen, Inspiration Biopharmaceuticals renegotiate strategic partnership

Tuesday, August 21, 2012 12:15 PM

Ipsen, a global specialty-driven pharmaceutical company, has renegotiated its 2010 strategic partnership agreement with Inspiration Biopharmaceuticals, a Cambridge, Mass.-based biopharmaceutical company focused on hemophilia, for the development and commercialization of Inspiration’s recombinant product portfolio.

More... »

Allergan, Molecular Partners form two exclusive alliances in eye disease

Tuesday, August 21, 2012 10:24 AM

Allergan, a multi-specialty health care company based in Medford, Mass., and Molecular Partners, a privately-owned Swiss biotech focused on a class of biological drugs known as DARPins, have significantly expanded their existing relationship by entering into two separate agreements to discover, develop and commercialize proprietary therapeutic DARPin products for the treatment of serious ophthalmic diseases.

More... »

Shire joins ABPI

Tuesday, August 21, 2012 09:56 AM

Specialty biopharmaceutical company Shire has joined the Association of the British Pharmaceutical Industry (ABPI) as a full member.

More... »

Breast cancer drug market will be driven by 3 agents, says Decision Resources

Monday, August 20, 2012 02:18 PM

Three new breast cancer market entrants—Roche/Genentech’s Perjeta (pertuzumab) and trastuzumab-DM1 (T-DM1), and Novartis’s Afinitor (everolimus)—will drive growth in the breast cancer market through 2021, according to Decision Resources, a research and advisory firm for pharmaceutical and healthcare issues.

More... »

Pharmacyclics triggers $50M milestone payment for mantle cell lymphoma trial

Monday, August 20, 2012 11:35 AM

Pharmacyclics, a clinical-stage biopharmaceutical company of Sunnyvale, Calif., announced that the clinical trial, SPARK, of ibrutinib in patients with relapsed or refractory mantle cell lymphoma (MCL) has enrolled its fifth patient, triggering a second $50 million milestone payment obligation from Janssen Biotech.

More... »

HUYA Bioscience, Tianjin Research Center form collaboration

Monday, August 20, 2012 10:03 AM

HUYA Bioscience International, focused on accelerating the global development of China’s pharmaceutical innovations, has formed a strategic partnership with Tianjin Research Center of Basic Medical Sciences (TJRCBMS), a nonprofit Chinese research institution.

More... »